Nuvalent | Investor Presentation Deck | 42 slides · page 17 of 42
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.
Pitch deck · appendix_data · analyze_data · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
list 2/2 paragraph 1/1 source-note 1/1 table 1/1 title 1/1
Components 6
bullet bullet paragraph source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.